Could a tiny eye implant save your sight from glaucoma?
NCT ID NCT02862938
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase 2 trial tests a small implant (NT-501) placed inside the eye to protect nerve cells and slow vision loss in people with glaucoma. 54 participants will either get the implant or a sham surgery, and their vision will be tracked for 2 years. The implant releases a protein that may keep retinal cells alive longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Byers Eye Institute at Stanford University
Palo Alto, California, 94303, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NT-501 encapsulated cell therapy implant
What this could lead to
If successful, this implant could slow or stop vision loss in glaucoma patients by continuously delivering protective proteins to the eye.
What could go wrong
This is a small, early-phase trial (54 people) with a sham surgery control. The implant requires eye surgery, which carries risks like infection or implant issues. Results may not confirm benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.